Tarsons Products Share News - Latest Updates, Live News & More

Latest news about Tarsons Products

Tarsons Products Limited Issues Postal Ballot Notice for Independent Director Appointment 10 days ago

Tarsons Products Limited has issued a postal ballot notice dated March 06, 2026, seeking shareholder approval for appointing Mr. Vinesh Mohan Kriplani (DIN: 08212644) as Non-Executive Independent Director for five consecutive years from February 06, 2026 to February 05, 2031. The remote e-voting period runs from March 07, 2026 at 09:00 A.M. to April 06, 2026 at 05:00 P.M. (IST), with results expected by April 08, 2026. Mr. Kriplani is a Chartered Accountant with 29 years of experience in corporate taxation and M&A, currently associated with Serum Institute of India.

Tarsons Products Releases Q3FY26 Earnings Conference Call Transcript Feb 11, 2026

Tarsons Products Limited Announces Q3 FY26 Financial Results with Strong Performance Feb 09, 2026

Tarsons Products Limited Schedules Q3FY26 Earnings Call for February 6, 2026 Jan 30, 2026

MUFG Reduces Stake in Tarsons Products to 1.43% Through Entity Sale Nov 28, 2025

More news about Tarsons Products

27Nov 25

Tarsons Products Injects EUR 3 Million into Singapore Subsidiary for Debt Repayment

Tarsons Products Limited has invested €3 million (approx. ₹27 crore) into its wholly-owned Singapore subsidiary, Tarsons Life Science Pte. Ltd. The investment involves acquiring 1,000 equity shares at €3,000 per share. The funds will be used for loan repayment, meeting operational financial obligations, and general corporate purposes. Tarsons Life Science Pte. Ltd. is a holding company for Tarsons' German operations. The investment aims to strengthen the company's global operations and streamline its financial structure. Necessary intimations have been made to the RBI, and there is no change in the ownership structure of the subsidiary.

19Nov 25

Tarsons Products Reports Mixed Q2 FY26 Results: Revenue Growth Amid Profit Decline

Tarsons Products Limited reported mixed Q2 FY26 results with revenue growth to INR 81.00 crores and EBITDA increase of 11% YoY to INR 26.00 crores. However, PAT declined to INR 6.50 crores due to higher depreciation expenses of INR 20.00 crores from partial capitalization of the Panchla facility. The company is nearing completion of capex at Panchla and Amta facilities, expected to be fully operational by Q4 FY26. Tarsons launched new products including bioprocess-related items and anticipates strong turnaround as utilization levels increase. Management expects new capacity to generate peak revenue potential of INR 350.00-400.00 crores over 3-5 years.

13Nov 25

Tarsons Products Reports Mixed H1FY26 Results: Revenue Growth Offset by Profit Decline

Tarsons Products Limited reported a 5.2% YoY revenue growth to Rs 193.70 crore in H1FY26. EBITDA increased by 18.4% to Rs 52.10 crore, and Cash PAT grew by 20.8% to Rs 47.50 crore. However, profit after tax declined significantly due to accelerated depreciation and higher finance costs from the new Panchla facility. The company expects revenue contribution from the new facility to begin in coming years, with rapid ramp-up anticipated from FY27. Management remains confident about future growth prospects, citing expanded capacities and new product additions.

12Nov 25

Tarsons Products Reports Mixed Q2 Results: Profit Dips, EBITDA Rises

Tarsons Products, an Indian labware company, released Q2 financial results showing a mixed performance. Net profit decreased by 49.61% to ₹65.00 million from ₹129.00 million in the previous year. However, EBITDA improved by 11.06% to ₹261.00 million, and the EBITDA margin expanded by 3.14 percentage points to 32.48%. The contrasting trends in net profit and EBITDA suggest improved operational efficiency but challenges impacting the bottom line.

19Aug 25

Tarsons Products Reports Mixed Q1 Results Amid Global Uncertainties

Tarsons Products Limited reported mixed Q1 results with 10% YoY standalone revenue growth to ₹71.00 crores and 8% consolidated revenue growth to ₹91.00 crores. Domestic business grew 12% YoY, while exports increased 3%. However, standalone PAT declined to ₹3.60 crores from ₹6.50 crores, and consolidated PAT fell to ₹1.80 crores from ₹4.00 crores. EBITDA improved with standalone EBITDA growing 31% YoY to ₹22.00 crores. The company commenced Phase 1 production at its new Panchla facility and expects Phase 2 operations in H2. Tarsons remains cautiously optimistic about future prospects despite industry challenges.

12Aug 25

Tarsons Products Reports Q1 Results: Revenue Growth Amidst Challenges

Tarsons Products Limited announced Q1 financial results with 7.7% YoY revenue growth to ₹913.64 crore on a consolidated basis. Standalone revenue grew 9.9% YoY to ₹712.79 crore, with domestic revenue up 12.3%. However, net profit declined to ₹17.83 crore from ₹40.16 crore YoY. The profitability drop is attributed to higher depreciation from the capitalization of the new Panchla facility. Management remains optimistic about future growth prospects, citing a strong order pipeline and potential from new product categories.

04Aug 25

Tarsons Products Reshapes Board with Strategic Appointments and Resignations

Tarsons Products Limited has announced significant changes to its board composition, effective August 4, 2025. Dr. Monjori Mitra, with 24 years of experience in infectious diseases and pediatrics, has been appointed as Additional Director (Non-Executive Independent). Mr. Ramanathan Subramanian Arun Kumar, representing Clear Vision Investment Holdings Pte Ltd, joins as Additional Director (Non-Executive Nominee). Mr. Suresh Eshwara Prabhala has resigned as Non-Executive Nominee Director but has been reappointed as Additional Director (Non-Executive Non-Independent). These appointments bring diverse expertise in medicine, finance, and corporate strategy to the company's leadership.

23Jul 25

Tarsons Products Appoints Divya Sameer Momaya as Independent Director with Overwhelming Shareholder Approval

Tarsons Products Limited has appointed Mrs. Divya Sameer Momaya as a Non-Executive Independent Director for a five-year term starting May 24, 2025. The appointment received overwhelming shareholder approval with 99.99% of votes in favor. Mrs. Momaya brings over 22 years of experience in corporate law, governance, and business development. She holds a Bachelor's degree in Commerce and is an Associate Member of the Institute of Company Secretaries of India.

28May 25

Tarsons Products Q4 Revenue Climbs, Profit Dips

Tarsons Products reported mixed Q4 results. Revenue increased 7.39% to ₹930.00 million, and EBITDA rose 9.14% to ₹370.00 million with an improved margin of 39.73%. However, standalone net profit declined 16.49% to ₹157.00 million compared to the previous year.

09Apr 25

Tarsons Products Settles €15 Million Earn-Out Obligation Ahead of Schedule

Tarsons Products Limited, an Indian laboratory plasticware manufacturer, has announced the early settlement of a €15 million earn-out obligation. The company pre-closed and discharged this obligation, which was initially issued as a corporate guarantee to PN Beteiligugns GmbH on behalf of its Singapore subsidiary, Tarsons Life Science Pte. Ltd. This transaction has been reported to the Reserve Bank of India, demonstrating regulatory compliance. The early settlement potentially improves Tarsons' financial flexibility, demonstrates financial strength, and reduces its liabilities.